Department of Urology, Division of Molecular Oncology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.
Department of Urology, Kameda Daiichi Hospital, Niigata 950-0165, Japan.
Curr Oncol. 2023 May 28;30(6):5350-5365. doi: 10.3390/curroncol30060406.
Advanced bladder cancer (BC) (local invasive and/or metastatic) is not curable even with cytotoxic chemotherapy, immune checkpoint inhibitors, and targeted treatment. Targeting GSK-3β is a promising novel approach in advanced BC. The induction of autophagy is a mechanism of secondary resistance to various anticancer treatments. Our objectives are to investigate the synergistic effects of GSK-3β in combination with autophagy inhibitors to evade GSK-3β drug resistance. Small molecule GSK-3β inhibitors and GSK-3β knockdown using siRNA promote the expression of autophagy-related proteins. We further investigated that GSK-3β inhibition induced the nucleus translocation of transcription factor EB (TFEB). Compared to the GSK-3β inhibition alone, its combination with chloroquine (an autophagy inhibitor) significantly reduced BC cell growth. These results suggest that targeting autophagy potentiates GSK-3β inhibition-induced apoptosis and retarded proliferation in BC cells.
高级膀胱癌(BC)(局部侵袭性和/或转移性)即使采用细胞毒性化疗、免疫检查点抑制剂和靶向治疗也无法治愈。靶向 GSK-3β 是治疗高级 BC 的一种有前途的新方法。自噬的诱导是对各种抗癌治疗产生继发耐药性的一种机制。我们的目标是研究 GSK-3β 与自噬抑制剂联合使用以规避 GSK-3β 耐药性的协同作用。小分子 GSK-3β 抑制剂和使用 siRNA 的 GSK-3β 敲低可促进自噬相关蛋白的表达。我们进一步研究发现,GSK-3β 抑制诱导转录因子 EB(TFEB)核易位。与单独的 GSK-3β 抑制相比,其与氯喹(一种自噬抑制剂)联合使用可显著降低 BC 细胞的生长。这些结果表明,靶向自噬可增强 GSK-3β 抑制诱导的凋亡并减缓 BC 细胞的增殖。